The Effect of Prolonged Glucagon-like Peptide 1 Infusion on Gastric Emptying in Healthy Volunteers
Mahesh Umapathysivam
10 participants
Jun 19, 2012
Interventional
Conditions
Summary
The study aims to identify whether there is reduction in the effect of GLP-1 on gastric emptying with prolonged infusion of GLP-1. Hypothesis The GLP-1's effect of slowing gastric emptying will be reduced over time.
Eligibility
Inclusion Criteria2
- Healthy
- Normal gastric functioning
Exclusion Criteria14
- Inability to give informed consent,
- Radiation exposure for research purposes in the past 12 months,
- The ARPANSA guidelines published by the Australian Government entitled Code of Practice Exposure of Humans to Ionizing Radiation for Research Purposes States that the dose constraints for a research participant is 5mSv per year and 10mSv for a 5 year period.
- History of diabetes,
- HbA1c >6.0,
- Taking medication that are known to effect gastrointestinal motility,
- Taking medication effecting blood glucose,
- Creatinine Clearance <100 ml/min (men), 90 ml/min (women)
- Pregnancy,
- Ferritin level < 20microg/L
- Previous surgery on the small intestine,
- Smoking >10 cigarettes per day
- Alcohol >20g per day
- Because of concerns of cumulative life time exposure to radiation, we will directly screen all volunteers as to their previous radiation exposure, and will exclude any volunteer who has received 3 or more examinations using a computerized tomogram and/or 10 or more examinations using standard x-rays.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Arm 1: intermittent GLP-1 infusion (0.8 pmol/kg/min over 2x4.5 hours separated by 19 hours) Arm 2: Acute GLP-1 infusion (0.8 pmol/kg/min over 4.5 hours)Arm 3: prolonged GLP-1 infusion(0.8 pmol/kg/min over 24 hours) Treatment order is randomised with a washout period of at least 3 days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612001035819